Richard Pazdur (via AACR)
FDA's top cancer leaders want to shift how companion diagnostics are regulated
The FDA is recognizing a major disconnect for some new cancer drugs. This idea that each new oncology drug approved is aligned at the time …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
